Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157423 | 0.85 | TSHR (0.37) | MAPTL3MBTL1KMT2AHTR2CHTR2B | |
| SCHEMBL27587475 | 0.84 | HTT (0.38) | MAPTL3MBTL1HTR2CHTR2BS1PR4 | |
| SCHEMBL1569483 | 0.81 | HTR2C (0.36) | MAPTL3MBTL1HTR2CHTR2BS1PR4 | |
| SCHEMBL5096842 | 0.81 | MAPT (0.50) | MAPTHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL1569687 | 0.80 | HTR2C (0.38) | MAPTL3MBTL1KMT2AHTR2CHTR2B | |
| SCHEMBL11850996 | 0.79 | ALDH1A1 (0.36) | MAPTL3MBTL1CSNK2A1KMT2AKDM4E | |
| SCHEMBL1404367 | 0.79 | KMT2A (0.41) | MAPTL3MBTL1KMT2AKDM4EMEN1 | |
| SCHEMBL20564353 | 0.78 | HPGD (0.41) | MAPTL3MBTL1CSNK2A1KMT2AKDM4E | |
| SCHEMBL5754501 | 0.78 | HTR2C (0.35) | MAPTCSNK2A1KMT2AHTR2CHTR2B | |
| SCHEMBL27760963 | 0.78 | HTT (0.33) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103384668-B | compounds and compositions for inhibition of NAMPT | 福马TM有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | claimed |
| JP-2012500216-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | claimed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | claimed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-110003199-A | Novel compound, material for organic electroluminescent element, and electronic device | 出光兴产株式会社 | 2019-07-12 | — | — | CN | disclosed |
| CN-107810175-A | The alternatively cyclopropyl-methylamine of the HT of property 5 (2C) receptor stimulating agent | 伊利诺伊大学评议会 | 2018-03-16 | — | — | CN | disclosed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-102459258-B | Preparation and use of 1,2, 4-triazolo [1,5a ] pyridine derivatives | CEPHALON, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-7211572-B2 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1544199-A1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| CN-1086696-C | Sulphonylamino (thio) carbonyl compounds | 拜尔公司 | 2002-06-26 | — | — | CN | disclosed |
| EP-0381434-A1 | Process for producing optically active alcohol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | MAPT 1533/4885L3MBTL1 700/4885PKM 4337/4885 |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | MAPT 3482/4885L3MBTL1 4677/4885PKM 2540/4885 |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | MAPT 1533/4885L3MBTL1 700/4885PKM 4337/4885 |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP1, FABP4 | MAPT 3579/4885L3MBTL1 4284/4885PKM 3269/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | MAPT 3482/4885L3MBTL1 4677/4885PKM 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.